As FDA Posts Waivers, House Okays Bill To Ban Panel Members With Conflicts
This article was originally published in The Gray Sheet
Executive Summary
FDA has begun publishing conflict of interest waivers on its website for outside experts prior to their participation in advisory panel meetings, even as lawmakers continue to push for legislation that would ban individuals with conflicts from participating at all
You may also be interested in...
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than a more extensive overhaul
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than a more extensive overhaul
MDMA Annual Meeting In Brief
CED is coming soon: Revised draft guidance on CMS' coverage-with-evidence development policy is expected out within "weeks," agency Administrator Mark McClellan said June 15 at the Medical Device Manufacturers Association annual meeting in Washington, D.C. Despite rumors following the first draft guidance that CED was dead in the water due to concerns about basing coverage on patient consent, the new version will address the issue (1"The Gray Sheet" May 8, 2006, p. 7). "We want to get this right," McClellan said...